Endo International plc (ENDP)
(Delayed Data from NSDQ)
$8.20 USD
+0.48 (6.22%)
Updated May 3, 2019 04:00 PM ET
After-Market: $8.19 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$8.20 USD
+0.48 (6.22%)
Updated May 3, 2019 04:00 PM ET
After-Market: $8.19 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Merck's (MRK) Keytruda Gets FDA Nod for Expanded Melanoma Use
by Zacks Equity Research
Post FDA approval, Merck's (MRK) anti-PD-1 therapy Keytruda is now approved as an adjuvant treatment for adult & pediatric patients with stage IIB, IIC or III melanoma following complete resection.
Dyne Therapeutics (DYN) Submits IND to FDA for DMD Candidate
by Zacks Equity Research
Dyne Therapeutics (DYN) files an investigational new drug application in the United States for a clinical study on its investigational candidate DYNE-251 to address Duchenne Muscular Dystrophy.
Sage (SAGE), Biogen (BIIB) Report Data on Depression Drug
by Zacks Equity Research
Sage Therapeutics (SAGE) and partner Biogen (BIIB) announce positive data from a cohort of an ongoing phase III study, currently evaluating their investigational major depressive disorder drug zuranolone.
Best Momentum Stocks to Buy for December 2nd
by Zacks Equity Research
CCRN, ENDP, GOOS, and TITN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 2, 2021.
AbbVie (ABBV) Files for Skyrizi to Treat Crohn's Disease in EU
by Zacks Equity Research
AbbVie (ABBV) submits a regulatory application in the European Union, seeking approval for risankizumab (Skyrizi) for the treatment of Crohn's disease.
Jazz (JAZZ) Begins Zepzelca Combo Study for First-Line SCLC
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) and partner Roche enrol the first patient in the phase III study to investigate the novel combination of Zepzelca and Tecentriq for small cell lung cancer.
ImmunoGen (IMGN) Surges on Successful Ovarian Cancer Study
by Zacks Equity Research
ImmunoGen (IMGN) reports successful completion of a pivotal study evaluating its lead pipeline candidate as monotherapy in certain ovarian cancer patients previously treated with Avastin.
Do Options Traders Know Something About Endo International (ENDP) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to for Endo International (ENDP) stock based on the movements in the options market lately.
Here Is Why Bargain Hunters Would Love Fast-paced Mover Endo (ENDP)
by Zacks Equity Research
Endo (ENDP) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
PhaseBio (PHAS) Dips on Mixed Data From Antiplatelet Drug Study
by Zacks Equity Research
PhaseBio's (PHAS) phase III study evaluating bentracimab for the reversal of antiplatelet effects of ticagrelor meets primary endpoint. The stock falls on high rates of the drug's side effects.
ChemoCentryx (CCXI) Gets Positive CHMP Opinion for Tavneos
by Zacks Equity Research
ChemoCentryx (CCXI) receives a positive recommendation from the CHMP for its lead drug Tavneos to treat two forms of ANCA-associated vasculitis.
Novo Nordisk (NVO) Gets Positive CHMP Opinion for Wegovy
by Zacks Equity Research
The CHMP gives a positive opinion on, and recommends approval to Novo Nordisk's (NVO) Wegovy for chronic weight management in adults with obesity.
Organon's (OGN) Earnings & Revenues Surpass Estimates in Q3
by Zacks Equity Research
Organon's (OGN) earnings and revenues trump estimates in the third quarter of 2021. Shares down in pre-market trading.
ChemoCentryx (CCXI) Q3 Loss Narrower Than Expected, Sales Top
by Zacks Equity Research
ChemoCentryx (CCXI) posts narrower-than-expected loss for third-quarter 2021. The company's revenues for the quarter also beat estimates.
Perrigo (PRGO) Misses on Q3 Earnings, Lowers Earnings View
by Zacks Equity Research
Perrigo (PRGO) reports dismal third-quarter 2021 results. Stock declines.
Jazz Pharma (JAZZ) Q3 Earnings Beat, New Drugs Drive Sales
by Zacks Equity Research
Jazz Pharma's (JAZZ) product revenues grow in the third quarter on the back of strong demand for its new drugs and drugs added with the acquisition of GW Pharmaceuticals.
Zacks.com featured highlights include: Endo International, SM Energy, CBRE Group, ON Semiconductor and Penske Automotive
by Zacks Equity Research
Zacks.com featured highlights include: Endo International, SM Energy, CBRE Group, ON Semiconductor and Penske Automotive
ACADIA's (ACAD) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
ACADIA Pharmaceuticals (ACAD) posts narrower-than-expected loss for the third quarter of 2021. Revenues also beat estimates. Resultantly, its shares rise in after-hours trading.
Here Is Why Bargain Hunters Would Love Fast-paced Mover Endo (ENDP)
by Zacks Equity Research
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Endo (ENDP) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
5 Stocks Investors Must Buy for Relative Price Strength
by Nilanjan Choudhury
Endo International (ENDP), SM Energy (SM), CBRE Group (CBRE), ON Semiconductor (ON) and Penske Automotive Group (PAG) are five stocks with explosive relative price strength.
Are You Looking for a Top Momentum Pick? Why Endo International (ENDP) is a Great Choice
by Zacks Equity Research
Does Endo International (ENDP) have what it takes to be a top stock pick for momentum investors? Let's find out.
Endo International (ENDP) Crossed Above the 200-Day Moving Average: What That Means for Investors
by Zacks Equity Research
Is it a good or bad thing when a stock surpasses resistance at the 200-day simple moving average?
Endo (ENDP) Beats Q3 Earnings & Sales Estimates, Raises View
by Zacks Equity Research
Endo (ENDP) tops third-quarter earnings and sales estimates and raises its forecast. Shares are up in pre-market trading.
Endo International (ENDP) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Endo (ENDP) delivered earnings and revenue surprises of 73.91% and 15.60%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Zoetis' (ZTS) Earnings and Revenues Surpass Estimates in Q3
by Kanishka Das
Zoetis' (ZTS) earnings and revenues beat estimates in the third quarter of 2021. The company raised its financial guidance for 2021.